Treatment of Pulmonary Disease Due to Mycobacterium kansasii: Recent Experience with Rifampin

Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were excluded. Response to treatment and posttreatment follow-up was evaluated in 162 patients. Overall, 135 patients (83%) achieved negative sputum...

Full description

Saved in:
Bibliographic Details
Published in:Reviews of infectious diseases Vol. 3; no. 5; pp. 1035 - 1039
Main Authors: Pezzia, W, Raleigh, J W, Bailey, M C, Toth, E A, Silverblatt, J
Format: Journal Article
Language:English
Published: United States University of Chicago Press 01-09-1981
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were excluded. Response to treatment and posttreatment follow-up was evaluated in 162 patients. Overall, 135 patients (83%) achieved negative sputum cultures within six months. Among 32 patients whose drug regimen included rifampin, all 32 (100%) had negative cultures at the fourth and fifth months, but two relapsed during the sixth month, with cultures resistant to 1.0 and 25 μg of rifampin/ml. Among 130 patients whose regimen did not include rifampin, negative sputum cultures were achieved by the sixth month in 101 (80%). In these patients, no significant influence could be attributed to (1) the use of three-drug vs. two-drug regimens; (2) the in vitro susceptibility of pretreatment cultures to isoniazid; (3) the coexistence of obstructive airway disease; or (4) the early use of pulmonary resection. The susceptibility of pretreatment cultures to streptomycin in those who received this drug may have influenced outcome. The late follow-up showed a cumulative relapse rate of 13% over five years in those who had achieved negative cultures initially, and the relapse rate did not appear to be influenced by pulmonary resection as part of the treatment.
AbstractList Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were excluded. Response to treatment and posttreatment follow-up was evaluated in 162 patients. Overall, 135 patients (83%) achieved negative sputum cultures within six months. Among 32 patients whose drug regimen included rifampin, all 32 (100%) had negative cultures at the fourth and fifth months, but two relapsed during the sixth month, with cultures resistant to 1.0 and 25 μg of rifampin/ml. Among 130 patients whose regimen did not include rifampin, negative sputum cultures were achieved by the sixth month in 101 (80%). In these patients, no significant influence could be attributed to (1) the use of three-drug vs. two-drug regimens; (2) the in vitro susceptibility of pretreatment cultures to isoniazid; (3) the coexistence of obstructive airway disease; or (4) the early use of pulmonary resection. The susceptibility of pretreatment cultures to streptomycin in those who received this drug may have influenced outcome. The late follow-up showed a cumulative relapse rate of 13% over five years in those who had achieved negative cultures initially, and the relapse rate did not appear to be influenced by pulmonary resection as part of the treatment.
Records of 244 patients with M. kansasii isolated from their sputum were reviewed. Overall, 135 patients achieved negative sputum cultures within six months. Among 32 patients whose drug regimen included rifampin, all 32 had negative cultures at the fourth and fifth months, but two relapsed during the sixth month, with cultures resistant to 1.0 and 25 mu g of rifampin/ml. Among 130 patients whose regimen did not include rifampin, negative sputum cultures were achieved by the sixth month in 101 (80%). In these patients, no significant influence could be attributed to (1) the use of three-drug vs. two-drug regimens; (2) the in vitro susceptibility of pretreatment cultures to isoniazid; (3) the coexistence of obstructive airway disease; or (4) the early use of pulmonary resection.
Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were excluded. Response to treatment and posttreatment follow-up was evaluated in 162 patients. Overall, 135 patients (83%) achieved negative sputum cultures within six months. Among 32 patients whose drug regimen included rifampin, all 32 (100%) had negative cultures at the fourth and fifth months, but two relapsed during the sixth month, with cultures resistant to 1.0 and 25 micrograms of rifampin/ml. Among 130 patients whose regimen did not include rifampin, negative sputum cultures were achieved by the sixth month in 101 (80%). In these patients, no significant influence could be attributed to (1) the use of three-drug vs. two-drug regimens; (2) the in vitro susceptibility of pretreatment cultures to isoniazid; (3) the coexistence of obstructive airway disease; or (4) the early use of pulmonary resection. The susceptibility of pretreatment cultures to streptomycin in those who received this drug may have influenced outcome. The late follow-up showed a cumulative relapse rate of 13% over five years in those who had achieved negative cultures initially, and the relapse rate did not appear to be influenced by pulmonary resection as part of the treatment.
Author Julian Silverblatt
James W. Raleigh
Margaret C. Bailey
Willy Pezzia
Elizabeth A. Toth
Author_xml – sequence: 1
  givenname: W
  surname: Pezzia
  fullname: Pezzia, W
– sequence: 2
  givenname: J W
  surname: Raleigh
  fullname: Raleigh, J W
– sequence: 3
  givenname: M C
  surname: Bailey
  fullname: Bailey, M C
– sequence: 4
  givenname: E A
  surname: Toth
  fullname: Toth, E A
– sequence: 5
  givenname: J
  surname: Silverblatt
  fullname: Silverblatt, J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/7339801$$D View this record in MEDLINE/PubMed
BookMark eNqFkDtPwzAYRT0UlVL4ByB5YovkxI84bKgtD6kIVJURRY79RbgkdogdQf89Qa1Yme5wzr3DPUMT5x1M0IykIkuIlOIUnYWwI4TTnIkpmuaUFpKkM_S27UHFFlzEvsYvQ9N6p_o9XtoAKgBeDoCjx0977SulI_R2aPGHckEFa2_wBvRvdfXdjQScBvxl4zve2Fq1nXXn6KRWTYCLY87R691qu3hI1s_3j4vbdbLLuIyJ5IRDRljGjFIVMVzmVU0LnfKCcJaq2phK5FwLDaQwecGNqE0uCqkoYbXQdI6uD7td7z8HCLFsbdDQNMqBH0KZUym5IPJfMeWMMML5KF4dxaFqwZRdb9vxl_J43MgvD3wXou__MGM8E0zSH2ZodFM
ContentType Journal Article
Copyright Copyright 1981 The University of Chicago
Copyright_xml – notice: Copyright 1981 The University of Chicago
DBID CGR
CUY
CVF
ECM
EIF
NPM
7QL
C1K
7X8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
Bacteriology Abstracts (Microbiology B)
MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 1039
ExternalDocumentID 7339801
4452648
Genre Journal Article
GroupedDBID .GJ
2AX
3O-
5RE
6.Y
AACGO
AAMVS
AANCE
AAPGJ
AAQQT
AAWDT
ABBHK
ABPLY
ABSAR
ABSMQ
ABTLG
ABXSQ
ACFRR
ACGFS
ACPQN
ACUTJ
ADZLD
AEKPW
AEUPB
AEXZC
AFFNX
AFYAG
AGKRT
ALMA_UNASSIGNED_HOLDINGS
AQDSO
AQKUS
AQVQM
AZFZN
BZKNY
DCCCD
DNJUQ
DOOOF
DWIUU
EIHJH
F5P
HQ3
HTVGU
J5H
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JSODD
JST
L7B
MBLQV
OBFPC
PB-
QBD
ROZ
SA0
TMA
ZGI
53G
ACMRT
ACZBC
ADACV
AFSHK
AGMDO
AVNTJ
CGR
CUY
CVF
ECM
EIF
IPSME
NPM
UAP
7QL
C1K
7X8
ID FETCH-LOGICAL-j258t-8505e20424daab0d587bf39c1590541afddb675c6ce09d795d6fd7698a304f6c3
IEDL.DBID JSG
ISSN 0162-0886
IngestDate Fri Oct 25 01:29:51 EDT 2024
Tue Aug 27 04:32:53 EDT 2024
Sat Sep 28 08:36:32 EDT 2024
Fri Feb 02 07:03:09 EST 2024
IsPeerReviewed false
IsScholarly false
Issue 5
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-j258t-8505e20424daab0d587bf39c1590541afddb675c6ce09d795d6fd7698a304f6c3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-2
ObjectType-Feature-1
content type line 23
SourceType-Conference Papers & Proceedings-1
ObjectType-Conference-3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
PMID 7339801
PQID 15404055
PQPubID 23462
PageCount 5
ParticipantIDs proquest_miscellaneous_73885608
proquest_miscellaneous_15404055
pubmed_primary_7339801
jstor_primary_4452648
PublicationCentury 1900
PublicationDate 1981 Sep-Oct
PublicationDateYYYYMMDD 1981-09-01
PublicationDate_xml – month: 09
  year: 1981
  text: 1981 Sep-Oct
PublicationDecade 1980
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Reviews of infectious diseases
PublicationTitleAlternate Rev Infect Dis
PublicationYear 1981
Publisher University of Chicago Press
Publisher_xml – name: University of Chicago Press
SSID ssj0053746
Score 1.2237619
Snippet Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were...
Records of 244 patients with M. kansasii isolated from their sputum were reviewed. Overall, 135 patients achieved negative sputum cultures within six months....
SourceID proquest
pubmed
jstor
SourceType Aggregation Database
Index Database
Publisher
StartPage 1035
SubjectTerms Adult
Aged
Antibacterials
Follow-Up Studies
Fungal infections
Fungal lung diseases
Humans
Isoniazid - pharmacology
Lung diseases
Male
Microbial Sensitivity Tests
Middle Aged
Mycobacterium Infections, Nontuberculous - drug therapy
Mycobacterium kansasii
Nontuberculous Mycobacteria - drug effects
Obstructive lung diseases
Pretreatment
Pulmonary tuberculosis
Relapse
Rifampin - therapeutic use
Session VI: Clinical Aspects
Sputum
Sputum - microbiology
Streptomycin - pharmacology
Tuberculosis, Pulmonary - drug therapy
Tuberculosis, Pulmonary - surgery
Title Treatment of Pulmonary Disease Due to Mycobacterium kansasii: Recent Experience with Rifampin
URI https://www.jstor.org/stable/4452648
https://www.ncbi.nlm.nih.gov/pubmed/7339801
https://search.proquest.com/docview/15404055
https://search.proquest.com/docview/73885608
Volume 3
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NT8IwGG6Eg_HiJ0T8wB64LrJ1XVtvRkBjgjGCiRdD2rVNUNgIsAP_3rcd0xOJ97VN3o_2WZ-n74tQhxlKjSQ6sILQIBbEBlJ248BoHSlhJRHaX12M2MsH7_VdmZxO9RbGySq9LtCz-ACQ1Mzcxq4PdsxrqMZ98j2PHqvdlhJWPsYJkyiAjEkqXeFuxOhPjsHR_9Y8RodbZIjvS1eeoD2TnaL94Zb7PkOf40oTjnOLX4sZBJBcbnCvpFhwrzB4nePhJoUU9SWYizn-dt3AV9PpHQZ86Ib-lTbG7goWv02tnC-mWQO9D_rjh6dg2xwh-IooXwccoIuJHHGppVRdTTlTlogU4AmgsFBarRX8DKRJarpCM0F1YjVLBJekG9skJU1Uz_LMnCOsAIVx5zMd6lgpKiOeWs6siQCOSZW2UMObZ7IoC2BMtrZpoZvKxBMISsc0yMzkxWoCuAw2B0p3f8EI5wC2YI5m6ZvfyRkhAo7Nix2LXqKDUPCwlHldofp6WZhrVFvpou31nG0fHj-9G7r7
link.rule.ids 315,782,786,808,811,58025,58037,58258,58270
linkProvider JSTOR
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ3PS8MwFMeDm6Be_C3OX8vBa7FtmibxJs4xcRuiE7xISZoEqq4b23rYf-9Lu-pp4L1J4L38-DTvm_cQumaGUiOJ9qwg1IsEsZ6UfuQZrUMlrCRCl1cXr2z4zjsPLk3Odf0WxskqS11gGcUHQFLf5iZydbAj3kCblPuEVcK9er-lhFXPcYI49GDNxLWycD0zlmdHd-9_o-6j3RUb4rvKmQdow-SHaGuwin4foY9RrQrHE4ufi2-YQnK2xJ0qyII7hcGLCR4sU1ikZRLmYoy_XD3weZbdYiBE1_QvuTF2l7D4JbNyPM3yY_TWfRjd97xVeQTvM6R84XGAFxO60KWWUvmacqYsESkACnBYIK3WCn4H0jg1vtBMUB1bzWLBJfEjG6fkBDXzSW5OEVbAYdx5TQc6UorKkKeWM2tCADKp0hY6Ls2TTKsUGMnKNi3Urk2cwLR0sQaZm0kxT4DMYHugdP0XjHAOuAV9nFS--e2cESLg4DxbM2gbbfdGg37Sfxw-naOdQPCgEn1doOZiVphL1Jjr4qqcJD9mXb1U
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ1LTwIxEIAbwYR48YkRX_TgwcsGdrvdtt6MQDQKIYqJF7Npt22CwkKAPfDvne6yeiLx3kcyM22_dqYzCN0wQ6mRRHtWEOqFglhPynboGa0DJawkQudPF29s8ME7XZcm57b8C-PCKvO4wNyLD4CkJqY117YVulrYIa-gXQqXGl7UBij3XEpY8SXHjwIP1k1URhdu58b8_Ogd_H_mQ7S_YUR8Xyj1CO2Y9BjV-hsv-An6HJXR4Xhm8TCbgCnJxRp3CmcL7mQGr2a4v05gsebJmLMp_nZ1wZfj8R0GUnRd_5IcY_cYi1_HVk7n47SO3nvd0cOjtymT4H2BIFYeB4gxgXNhailVW1POlCUiAVABHvOl1VrBtSCJEtMWmgmqI6tZJLgk7dBGCTlF1XSWmjOEFfAYd9rTvg6VojLgieXMmgDATKqkgeq5iOJ5kQoj3simgZqlmGMwT-dzkKmZZcsYCA22CUq3t2CEc8AuGOO00M_v4IwQAQfo-ZZJm6g27PTil6fB8wXa8wX3i9ivS1RdLTJzhSpLnV3ndvIDkkq_zQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+Pulmonary+Disease+Due+to+Mycobacterium+kansasii%3A+Recent+Experience+with+Rifampin&rft.jtitle=Reviews+of+infectious+diseases&rft.au=Willy+Pezzia&rft.au=James+W.+Raleigh&rft.au=Margaret+C.+Bailey&rft.au=Elizabeth+A.+Toth&rft.date=1981-09-01&rft.pub=University+of+Chicago+Press&rft.issn=0162-0886&rft.volume=3&rft.issue=5&rft.spage=1035&rft.epage=1039&rft.externalDocID=4452648
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0162-0886&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0162-0886&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0162-0886&client=summon